FTSE Russell Summit Therapeutics (2596D)
February 17 2020 - 11:30AM
UK Regulatory
TIDMSUMM
RNS Number : 2596D
FTSE Russell
17 February 2020
Summit Therapeutics (UK): Constituent Deletion
Changes in FTSE UK Index Series
17 February 2020
Subject to the expected cancellation of trading on AIM for Summit Therapeutics (UK, constituent),
please see details of affected indexes and effective dates below:
Index Effective From
Start of Trading
FTSE AIM All-Share Index 24 February 2020
For further information please contact FTSE Russell Client Services at info@ftserussell.com
or call: Australia +1800 653 680
Hong Kong +852 2164 3333
Japan +81 3 4563 6346
London +44 (0) 20 7866 1810
New York +1866 551 0617
Alternatively please visit our website at www.ftserussell.com
Terms of Use | Copyright (c) 2020 FTSE Russell
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
FTSUBANRRNUUAAR
(END) Dow Jones Newswires
February 17, 2020 12:30 ET (17:30 GMT)
Summit Therapeutics (LSE:SUMM)
Historical Stock Chart
From Dec 2024 to Jan 2025
Summit Therapeutics (LSE:SUMM)
Historical Stock Chart
From Jan 2024 to Jan 2025
Real-Time news about Summit Therapeutics Plc (London Stock Exchange): 0 recent articles
More Summit Therapeutics Plc News Articles